Newsroom

News

For many diseases, the tools of medicine are reaching their limits. CRISPR technologies open new avenues for diagnostics and therapies, although the natural source of CRISPR remains largely untapped. Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg, a joint venture of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Julius Maximilian University (JMU) Würzburg, now demonstrate a new way to study CRISPR systems that can accelerate their conversion into tools. Their approach was published today in the journal Molecular Cell.

24.02.2022

HIRI

News

Liver cancer is the third most common cause of cancer-related deaths worldwide. So far, the treatment options for two types of liver cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), have been inadequate, while the number of new cases has been rising. A study by researchers at the Hannover Medical School (MHH) and the Helmholtz Centre for Infection Research (HZI) now offers hope. A vaccine based on a highly attenuated infectious agent called Listeria monocytogenes proved to be safe and effective protection in premalignant and malignant liver diseases in preclinical mouse models.

18.02.2022

HZI Campus

News

An international research team from TWINCORE - Centre for Experimental and Clinical Infection Research, a joint facility of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and the Hannover Medical School, describes the dual effect of the endogenous substance itaconic acid, which is both antiviral and anti-inflammatory. Their study, which has now appeared in the journal PLoS Pathogens, opens up perspectives for possible therapeutic applications of itaconic acid against severe courses of disease in viral infections.

17.02.2022

HZI Campus

TWINCORE

Fruchtkörper von Myxobakterien unter dem Lichtmikroskop

News

Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections. Myxobiotics’ approach is based on a new class of natural compounds (cystobactamids) discovered and developed as antibacterial agents by Prof Rolf Müller and Prof Mark Brönstrup and their teams at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Helmholtz Centre for Infection Research (HZI), together with Dr Thomas Hesterkamp and Evotec. The HIPS is a site of the HZI in collaboration with Saarland University.

04.02.2022

HZI Campus

HIPS

News

The Minister President of Lower Saxony, Stephan Weil, visited the Helmholtz Centre for Infection Research (HZI) today, 4 February 2022. The visit focused on the current challenges and innovative approaches, especially in combating the SARS-CoV-2 pandemic, and the future development of infection research in Lower Saxony. He also delivered a message of thanks to the scientists at the research centre in Braunschweig.

04.02.2022

HZI Campus

News

Viruses are mostly encountered as pathogens. However, virus-based vaccination platforms can also help to provide protection from different diseases. In a mouse model, researchers from the Helmholtz Centre for Infection Research (HZI) in Braunschweig together with national and international partners including the German Center for Infection Research (DZIF), the German Primate Center – Leibniz Institute for Primate Research (DPZ), the Technische Universität Braunschweig and the University of Rijeka, Croatia, have developed a novel cytomegalovirus-based vaccine against different respiratory viruses. A single dose of the vaccine that consists of a cytomegalovirus that incorporates genes from coronavirus or influenza A efficiently protected mice from the respiratory infections. The results on the vaccine candidate, which is not yet market-ready, were published in the journal Cellular & Molecular Immunity.

17.01.2022

HZI Campus

Back to the first page
...
58
59
60
61
...
161

HZI in the media

Technische Universität Braunschweig, das HZI – Helmholtz-Zentrum für Infektionsforschung in Braunschweig sowie die Medizinische Hochschule ...

03.09.2026

Regierungsportal M-V

... des Exzellenzclusters RESIST und des Helmholtz-Instituts für RNA-basierte Infektionsforschung (HIRI) in Würzburg haben nun ...

03.09.2026

Bio M

international institutions including Trinity College Dublin, the Helmholtz Institute for One Health, Université Paris 1 Panthéon-Sorbonne,

02.09.2026

EurekAlert!

... die präzise Zerspanung großer Bauteile. Das Helmholtz-Zentrum für Infektionsforschung in Braunschweig und die Medizinische Hochschule ...

01.09.2026

Regionalupdate.de

... zunehmen. Mit der Gründung des HIOH im Jahr 2021 als Standort des Braunschweiger Helmholtz-Zentrums für ...

31.08.2026

Management & Krankenhaus

Wie man sich mit Mpox anstecken kann und warum sich Personen mit häufig wechselnden Sexpartnern impfen lassen sollten.

28.08.2026

Apotheken Umschau

... des neuen Forschungsgebäudes des Helmholtz-Instituts für One Health (HIOH) in Greifswald (Landkreis Vorpommern-Greifswald) gelegt

. ...

28.08.2026

Tagesschau

How Bacteria Develop Resistance to Antisense Antibiotics—and How Future Therapies Can Be Made Less Susceptible to It

28.08.2026

Bionity.COM

Infection Research; the RESIST Cluster of Excellence; and the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg has

27.08.2026

Phys.org

... Arbeiten am Universitätsklinikum Köln und am Helmholtz-Zentrum für Infektionsforschung startet nun die Entwicklung und GMP- ...

26.08.2026

healthcare-in-europe.com

Infos: Herpesviren – Eine große Familie Helmholtz Zentrum für Infektionsforschung www.helmholtz-hzi.de/wissen/wissensportal/ ...

25.08.2026

SWR4 Rheinland-Pfalz

An einer weiteren Station veranschaulicht das Helmholtz-Institut für Pharmazeutische Forschung, wie die Entwicklung neuer ...

25.08.2026

MSN Deutschland

Register now for the HZI newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.